DOCSLIB.ORG

Supplementary Table S1 List of Antibodies Against Total-, Phospho- and Cleaved-Proteins, with Dilutions Used for RPPA Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S1 List of Antibodies Against Total-, Phospho- and Cleaved-Proteins, with Dilutions Used for RPPA Analysis Supplementary Table S1 List of antibodies against total-, phospho- and cleaved-proteins, with dilutions used for RPPA analysis. ANTIBODY COMPANY CAT. # DILUTION 4E-BP1 Cell Signaling 9452 1:200 4E-BP1 (S65) Cell Signaling 9451 1:50 4E-BP1 (T37/46) Cell Signaling 9459 1:100 4E-BP1 (T70) Cell Signaling 9455 1:200 Acetil-CoA Carboxylase (S79) Cell Signaling 3661 1:50 Ack1 (Y284) Cell Signaling 3138 1:50 Ack1 (Y857/858) Cell Signaling 3137 1:100 Adducin (S662) Upstate 06-820 1:100 AKT Cell Signaling 9272 1:2000 AKT (S473) Cell Signaling 9271 1:100 AKT (T308) Cell Signaling 9275 1:100 ALK (Y1586) Cell Signaling 3348 1:200 AMPK alpha1 (S485) Cell Signaling 4184 1:50 AMPK beta1 (S108) Cell Signaling 4181 1:50 a-Raf (S299) Cell Signaling 4431 1:50 Arrestin1 (S412) Cell Signaling 2416 1:100 ASK1 (S83) Cell Signaling 3761 1:50 ATF-2 (T69/71) Cell Signaling 9225 1:500 ATF-2 (T71) Cell Signaling 9221 1:100 ATP-Cytrate Lyase (S454) Cell Signaling 4331 1:100 Aurora A (T288)/B (T232)/C (T198) Cell Signaling 2914 1:50 BAD Cell Signaling 9292 1:1000 BAD (S112) Cell Signaling 9291 1:200 BAD (S136) Cell Signaling 9295 1:50 BAD (S155) Cell Signaling 9297 1:100 BAK Cell Signaling 3792 1:100 BAX Cell Signaling 2772 1:200 Bcl-2 Cell Signaling 2872 1:100 Bcl-2 (S70) Cell Signaling 2827 1:50 Bcl-2 (T56) Cell Signaling 2875 1:200 Bcl-xL Cell Signaling 2762 1:500 Bcr (Y177) Cell Signaling 3901 1:500 Beclin1 Cell Signaling 3738 1:100 beta Catenin (T41/S45) Cell Signaling 9565 1:50 BMI-1 Chemicon MAB4376 1:100 b-Raf (S445) Cell Signaling 2696 1:50 Bub3 BD 611730 1:500 c-Abl (T735) Cell Signaling 2864 1:50 c-Abl (Y245) Cell Signaling 2861 1:100 Federici et al. Caspase 9 Cell Signaling 9502 1:200 Chk-1 (S345) Cell Signaling 2341 1:50 Chk-2 (S33/35) Cell Signaling 2665 1:50 c-Kit Zymed 34-8800 1:500 c-Kit (Y703) Cell Signaling 3073 1:50 c-Kit (Y719) Cell Signaling 3391 1:50 cleaved Caspase 3 (D175) Cell Signaling 9661 1:50 cleaved Caspase 6 (D162) Cell Signaling 9761 1:50 cleaved Caspase 7 (D198) Cell Signaling 9491 1:100 cleaved Caspase 9 (D315) Cell Signaling 9505 1:100 cleaved Caspase 9 (D330) Cell Signaling 9501 1:50 cleaved Lamin A (D230) Cell Signaling 2031 1:100 cleaved PARP (D214) Cell Signaling 9541 1:100 Cofilin (S3) Cell Signaling 3313 1:100 Cox-2 BD 610203 1:200 cPLA2 (S505) Cell Signaling 2831 1:1000 c-Raf (S338) Cell Signaling 9427 1:200 CREB Cell Signaling 9192 1:200 CREB (S133) Cell Signaling 9191 1:100 CrkII (Y221) Cell Signaling 3491 1:100 CrkL (Y207) Cell Signaling 3181 1:100 Cyclin A Cell Signaling 4656 1:50 Cyclin B1 Cell Signaling 4135 1:200 Cyclin D1 BD 554180 1:100 E-Cadherin Cell Signaling 4065 1:100 EGFR Cell Signaling 2232 1:100 EGFR (S1046/1047) Cell Signaling 2238 1:500 EGFR (Y1045) Cell Signaling 2237 1:50 EGFR (Y1068) Cell Signaling 2234 1:50 EGFR (Y1148) BioSource 44-792 1:100 EGFR (Y1173) BioSource 44-794 1:100 EGFR (Y845) Cell Signaling 2231 1:500 EGFR (Y992) Cell Signaling 2235 1:50 eIF4E (S209) Cell Signaling 9741 1:50 elF4G (S1108) Cell Signaling 2441 1:1000 Elk-1 (S383) Cell Signaling 9181 1:100 eNOS (S113) Cell Signaling 9575 1:50 eNOS (S1177) Cell Signaling 9571 1:50 eNOS-NOSIII (S116) Upstate 07-357 1:500 ErbB2 DAKO A0485 1:200 ErbB2 (Y1248) Imgenex IMG-90189 1:500 ErbB3 Cell Signaling 4754 1:500 ErbB3 (Y1197) Cell Signaling 4561 1:200 Federici et al. ErbB3 (Y1289) Cell Signaling 4791 1:200 ErbB4 Cell Signaling 4795 1:50 ERK1/2 Cell Signaling 9102 1:200 ERK1/2 (T202/Y204) Cell Signaling 9101 1:1000 Estrogen Receptor alpha DAKO M7047 1:50 Estrogen Receptor alpha (S118) Cell Signaling 2511 1:1000 Ezrin (T567)/Radixin (T564)/Moesin (T558) Cell Signaling 3141 1:100 FADD (S194) Cell Signaling 2781 1:100 FAK (Y397) BD 611806 1:50 FAK (Y576/577) Cell Signaling 3281 1:200 FKHR (S256) Cell Signaling 9461 1:100 FKHR (T24)/FKHRL1 (T32) Cell Signaling 9464 1:200 FKHRL1 (S253) Upstate 06-953 1:1000 FRS2 alpha (Y436) Cell Signaling 3861 1:50 Gab1 (Y627) Cell Signaling 3231 1:1000 GSK3 alpha/beta (S21/9) Cell Signaling 9331 1:100 GSK3 alpha/beta (Y279/216) BioSource 44-604 1:500 HIF-1 alpha BD 610958 1:50 Histone H3 (S10) mitosis marker Upstate 06-570 1:200 Histone H3 (S28) Upstate 07-145 1:1000 IGF-1R (Y1131)/Insulin Receptor (Y1146) Cell Signaling 3021 1:500 IGF-1R (Y1135/1136)/ Cell Signaling 3024 1:500 Insulin Receptor (Y1150/1151) IkB alpha (S32/36) Cell Signaling 9246 1:100 Insulin Receptor beta Cell Signaling 3025 1:200 IRS-1 Cell Signaling 2382 1:500 IRS-1 (S612) Cell Signaling 2386 1:200 Jak1 (Y1022/1023) Cell Signaling 3331 1:50 Jak2 (Y1007/1008) Cell Signaling 3771 1:500 Lck (Y505) Biosource 44-850 1:50 LKB1 (S334) Cell Signaling 3055 1:50 LKB1 (S428) Cell Signaling 3051 1:100 MARCKS (S152/156) Cell Signaling 2741 1:200 MEK 1/2 Cell Signaling 9122 1:500 MEK1/2 (S217/221) Cell Signaling 9121 1:500 Met (Y1234/1235) Cell Signaling 3126 1:200 MSK1 (S360) Cell Signaling 9594 1:50 Mst1 (T183)/Mst2 (T180) Cell Signaling 3681 1:50 mTOR Cell Signaling 2972 1:200 mTOR (S2448) Cell Signaling 2971 1:100 mTOR (S2481) Cell Signaling 2974 1:100 NFkB p65 (S536) Cell Signaling 3031 1:100 p27 (T187) Zymed 71-7700 1:200 p38 MAPK Cell Signaling 9212 1:200 Federici et al. p38 MAPK (T180/Y182) Cell Signaling 9211 1:100 p40 phox (T154) Cell Signaling 4311 1:500 p53 Cell Signaling 9282 1:5000 p53 (S15) Cell Signaling 9284 1:1000 p70 S6 Kinase Cell Signaling 9202 1:100 p70 S6 Kinase (S371) Cell Signaling 9208 1:50 p70 S6 Kinase (T389) Cell Signaling 9205 1:100 p70 S6 Kinase (T412) Upstate 07-018 1:500 p90RSK (S380) Cell Signaling 9341 1:400 PAK1 (S199/204)/PAK2 (S192/197) Cell Signaling 2605 1:50 PAK1 (T423)/PAK2 (T402) Cell Signaling 2601 1:100 Paxillin (Y118) Cell Signaling 2541 1:500 PDGFR beta Cell Signaling 3169 1:200 PDGFR beta (Y716) Upstate 07-021 1:200 PDGFR beta (Y751) Cell Signaling 3161 1:50 PDK1 (S241) Cell Signaling 3061 1:200 PKA C (T197) Cell Signaling 4781 1:200 PKC alpha (S657) Upstate 06-822 1:1000 PKC alpha/betaII (T638/641) Cell Signaling 9375 1:100 PKC delta (T505) Cell Signaling 9374 1:50 PKC pan/betaII (S660) Cell Signaling 9371 1:200 PKC theta (T538) Cell Signaling 9377 1:100 PKC zeta/lambda (T410/403) Cell Signaling 9378 1:50 PLC gamma1 (Y783) Cell Signaling 2821 1:100 PLK1 Cell Signaling 4535 1:100 PLK1 (T210) BD 558400 1:200 PRAS40 (T246) BioSource 44-1100 1:1000 PRK1 (T774)/PRK2 (T816) Cell Signaling 2611 1:100 Progesteron Receptor (S190) Cell Signaling 3171 1:50 pTEN Cell Signaling 9552 1:50 pTEN (S380) Cell Signaling 9551 1:500 Pyk2 (Y402) Cell Signaling 3291 1:200 Raf (S259) Cell Signaling 9421 1:100 Ras-GFR1 (S916) Cell Signaling 3321 1:50 Ret (Y905) Cell Signaling 3221 1:100 RSK3 (T356/S360) Cell Signaling 9348 1:500 S6 Ribosomal Protein (S235/236) Cell Signaling 4856 1:200 S6 Ribosomal Protein (S240/244) Cell Signaling 2215 1:1000 SAPK/JNK (T183/Y185) Cell Signaling 9251 1:100 SEK1/MKK4 (S80) Cell Signaling 9155 1:50 SGK1 (S78) Cell Signaling 5599 1:100 Shc (Y317) Upstate 07-206 1:200 SHIP1 (Y1020) Cell Signaling 3941 1:50 Federici et al. SHP2 (Y580) Biosource 44-558 1:500 Smac/Diablo Cell Signaling 2954 1:10,000 Smad1 (S/S)/Smad5(S/S)/Smad8(S/S) Cell Signaling 9511 1:50 Smad2 (S245/250/255) Cell Signaling 3104 1:100 Smad2 (S465/467) Cell Signaling 3101 1:200 Src (Y527) Cell Signaling 2105 1:200 Src family (Y416) Cell Signaling 2101 1:200 Stat1 (Y701) Cell Signaling 9171 1:1000 Stat2 (Y690) Cell Signaling 4441 1:200 Stat3 Cell Signaling 9132 1:1000 Stat3 (S727) Cell Signaling 9134 1:100 Stat3 (Y705) Upstate 05-485 1:200 Stat5 (Y694) Cell Signaling 9351 1:50 Stat6 (Y641) Cell Signaling 9361 1:100 Survivin Cell Signaling 2808 1:100 Syk (Y525/526) Cell Signaling 2711 1:50 Tuberin/TSC2 (Y1571) Cell Signaling 3614 1:50 Tyk2 (Y1054/1055) Cell Signaling 9321 1:500 Vav3 (Y173) Biosource 44-488 1:1000 VEGFR2 Cell Signaling 2479 1:200 VEGFR2 (Y1175) Cell Signaling 2478 1:50 VEGFR2 (Y951) Cell Signaling 2471 1:200 VEGFR2 (Y996) Cell Signaling 2474 1:100 Vimentin Cell Signaling 3295 1:500 XIAP Cell Signaling 2042 1:100 Zap-70 (Y319)/Syk (Y352) Cell Signaling 2701 1:400 Federici et al. .
Load more

Recommended publications
  • Anti-PRKCA / PKC-Alpha Antibody (Aa623-672) Rabbit Anti Human Polyclonal Antibody Catalog # ALS17942
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-PRKCA / PKC-Alpha Antibody (aa623-672) Rabbit Anti Human Polyclonal Antibody Catalog # ALS17942 Specification Anti-PRKCA / PKC-Alpha Antibody (aa623-672) - Product Information Application IHC-P, E Primary Accession P17252 Predicted Human, Mouse, Rat Host Rabbit Clonality Polyclonal Isotype IgG Calculated MW 76750 Anti-PRKCA / PKC-Alpha Antibody (aa623-672) - Additional Information Gene ID 5578 Alias Symbol PRKCA Other Names PRKCA, Aging-associated gene 6, AAG6, Alpha PKC, PKC-A, Pkcalpha, Protein kinase C alpha type, PKC Alpha, PKC-alpha, PKCA, Protein kinase c alpha, Protein kinase C, alpha Target/Specificity PRKCA Antibody detects endogenous levels of total PRKCA protein. Reconstitution & Storage Immunoaffinity purified Precautions Anti-PRKCA / PKC-Alpha Antibody (aa623-672) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-PRKCA / PKC-Alpha Antibody (aa623-672) - Protein Information Name PRKCA Synonyms PKCA, PRKACA Function Page 1/4 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Calcium-activated, phospholipid- and diacylglycerol (DAG)- dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells.
    [Show full text]
  • Generation of the Catalytic Fragment of Protein Kinase C Alpha in Vasospastic Canine Basilar Artery
    Neurosurg Focus 3 (4):Article 4, 1997. Generation of the catalytic fragment of protein kinase C alpha in vasospastic canine basilar artery Motohiko Sato, M.D., Eiichi Tani, M.D., Tsuyoshi Matsumoto, M.D., Hirokazu Fujikawa, M.D., and Shinobu Imajoh-Ohmi, Ph.D. Department of Neurosurgery, Hyogo College of Medicine, Hyogo, Japan; and Institute of Medical Science, University of Tokyo, Tokyo, Japan In previous studies of topical application of calphostin C, a specific inhibitor of the regulatory domain of protein kinase C (PKC), and calpeptin, a selective inhibitor of calpain, to spastic canine basilar artery (BA) researchers have suggested that the catalytic fragment of PKC (known as PKM) is probably formed by a limited proteolysis of continuously activated µ-calpain, but there has been no direct evidence for PKM formation in vasospasm. The present immunoblot study with anti-PKC-alpha antibody shows a significant decrease in cytosolic 80-kD PKC-alpha and a concomitantly significant increase in membrane PKC-alpha in the spastic canine BA. In addition, an immunoblot study in which cleavage site­directed antibodies were used demonstrated a significant increase in immunoreactive 45-kD PKM. The changes in membrane PKC-alpha and PKM were enhanced with the lapse of time after subarachnoid hemorrhage. The cleavage site­directed antibodies distinguish the proteolyzed from the unproteolyzed forms of PKC for in situ analyses of enzyme regulation mediated by proteolysis. The data indicate that PKC-alpha in spastic canine BA is translocated to the cell membrane, where PKC-alpha is rapidly cleaved into PKM as a result of proteolysis of the isozyme by µ-calpain but not by m-calpain.
    [Show full text]
  • PKC Alpha Rabbit Pab
    Leader in Biomolecular Solutions for Life Science PKC alpha Rabbit pAb Catalog No.: A13342 Basic Information Background Catalog No. Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that A13342 can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved Observed MW in diverse cellular signaling pathways. PKC family members also serve as major 85kDa receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The Calculated MW protein encoded by this gene is one of the PKC family members. This kinase has been 76kDa reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice Category suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. Primary antibody Applications WB Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 5578 P17252 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 523-672 of human PKC alpha (NP_002728.1). Synonyms PRKCA;AAG6;PKC-alpha;PKCA;PRKACA;PKC alpha Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using PKC alpha antibody (A13342) at 1:1000 dilution.
    [Show full text]
  • The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy
    International Journal of Molecular Sciences Review The Role of Z-disc Proteins in Myopathy and Cardiomyopathy Kirsty Wadmore 1,†, Amar J. Azad 1,† and Katja Gehmlich 1,2,* 1 Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK; [email protected] (K.W.); [email protected] (A.J.A.) 2 Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected]; Tel.: +44-121-414-8259 † These authors contributed equally. Abstract: The Z-disc acts as a protein-rich structure to tether thin filament in the contractile units, the sarcomeres, of striated muscle cells. Proteins found in the Z-disc are integral for maintaining the architecture of the sarcomere. They also enable it to function as a (bio-mechanical) signalling hub. Numerous proteins interact in the Z-disc to facilitate force transduction and intracellular signalling in both cardiac and skeletal muscle. This review will focus on six key Z-disc proteins: α-actinin 2, filamin C, myopalladin, myotilin, telethonin and Z-disc alternatively spliced PDZ-motif (ZASP), which have all been linked to myopathies and cardiomyopathies. We will summarise pathogenic variants identified in the six genes coding for these proteins and look at their involvement in myopathy and cardiomyopathy. Listing the Minor Allele Frequency (MAF) of these variants in the Genome Aggregation Database (GnomAD) version 3.1 will help to critically re-evaluate pathogenicity based on variant frequency in normal population cohorts.
    [Show full text]
  • AGC Kinases in Mtor Signaling, in Mike Hall and Fuyuhiko Tamanoi: the Enzymes, Vol
    Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This chapter was originally published in the book, The Enzymes, Vol .27, published by Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research and educational use including without limitation use in instruction at your institution, sending it to specific colleagues who know you, and providing a copy to your institution’s administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier's permissions site at: http://www.elsevier.com/locate/permissionusematerial From: ESTELA JACINTO, AGC Kinases in mTOR Signaling, In Mike Hall and Fuyuhiko Tamanoi: The Enzymes, Vol. 27, Burlington: Academic Press, 2010, pp.101-128. ISBN: 978-0-12-381539-2, © Copyright 2010 Elsevier Inc, Academic Press. Author's personal copy 7 AGC Kinases in mTOR Signaling ESTELA JACINTO Department of Physiology and Biophysics UMDNJ-Robert Wood Johnson Medical School, Piscataway New Jersey, USA I. Abstract The mammalian target of rapamycin (mTOR), a protein kinase with homology to lipid kinases, orchestrates cellular responses to growth and stress signals. Various extracellular and intracellular inputs to mTOR are known. mTOR processes these inputs as part of two mTOR protein com- plexes, mTORC1 or mTORC2. Surprisingly, despite the many cellular functions that are linked to mTOR, there are very few direct mTOR substrates identified to date.
    [Show full text]
  • N-Glycan Trimming in the ER and Calnexin/Calreticulin Cycle
    Neurotransmitter receptorsGABA and A postsynapticreceptor activation signal transmission Ligand-gated ion channel transport GABAGABA Areceptor receptor alpha-5 alpha-1/beta-1/gamma-2 subunit GABA A receptor alpha-2/beta-2/gamma-2GABA receptor alpha-4 subunit GABAGABA receptor A receptor beta-3 subunitalpha-6/beta-2/gamma-2 GABA-AGABA receptor; A receptor alpha-1/beta-2/gamma-2GABA receptoralpha-3/beta-2/gamma-2 alpha-3 subunit GABA-A GABAreceptor; receptor benzodiazepine alpha-6 subunit site GABA-AGABA-A receptor; receptor; GABA-A anion site channel (alpha1/beta2 interface) GABA-A receptor;GABA alpha-6/beta-3/gamma-2 receptor beta-2 subunit GABAGABA receptorGABA-A receptor alpha-2receptor; alpha-1 subunit agonist subunit GABA site Serotonin 3a (5-HT3a) receptor GABA receptorGABA-C rho-1 subunitreceptor GlycineSerotonin receptor subunit3 (5-HT3) alpha-1 receptor GABA receptor rho-2 subunit GlycineGlycine receptor receptor subunit subunit alpha-2 alpha-3 Ca2+ activated K+ channels Metabolism of ingested SeMet, Sec, MeSec into H2Se SmallIntermediateSmall conductance conductance conductance calcium-activated calcium-activated calcium-activated potassium potassium potassiumchannel channel protein channel protein 2 protein 1 4 Small conductance calcium-activatedCalcium-activated potassium potassium channel alpha/beta channel 1 protein 3 Calcium-activated potassiumHistamine channel subunit alpha-1 N-methyltransferase Neuraminidase Pyrimidine biosynthesis Nicotinamide N-methyltransferase Adenosylhomocysteinase PolymerasePolymeraseHistidine basic
    [Show full text]
  • PKC Alpha Affects Cell Cycle Progression and Proliferation in Human RPE Cells Through the Downregulation of P27kip1
    Molecular Vision 2009; 15:2683-2695 <http://www.molvis.org/molvis/v15/a285> © 2009 Molecular Vision Received 12 June 2009 | Accepted 3 December 2009 | Published 10 December 2009 PKC alpha affects cell cycle progression and proliferation in human RPE cells through the downregulation of p27kip1 Qianying Gao, Juan Tan, Ping Ma, Jian Ge, Yaqin Liu, Xuerong Sun, Lian Zhou State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China Purpose: Protein kinase C (PKC) plays an important role in the regulation of retinal pigment epithelium (RPE) cell proliferation. In this study, we investigated which of these isozymes could be responsible for the cell cycle and proliferation in human RPE cells. Methods: The effect of PKC activators on human RPE cell cycle progression was tested by flow cytometry. To identify the isoform of PKC responsible for the increased progression of the cells through the cell cycle, we monitored the effect of phorbol 12-myristate 13-acetate (PMA) on the subcellular localization of the nine PKC isoforms expressed in RPE cells. To evaluate the molecular mechanism by which PKCα induces cell cycle progression, we examined the transcript, protein, and cellular levels of cell cycle regulatory proteins using RT–PCR, western blotting, and a confocal microscope, respectively. Results: We demonstrated that PKC activation by PMA affected cell cycle progression in RPE cells. Of the nine PKC isoforms that were present in RPE cells, we found PKCα was both necessary and sufficient to promote cell cycle progression after being stimulated with PMA. Decreased PKCα expression resulted in a significant decrease in cell proliferation.
    [Show full text]
  • Distinct Regulation of Cardiac Fibroblast Proliferation and Transdifferentiation by Classical and Novel Protein Kinase C Isoform
    Molecular Pharmacology Fast Forward. Published on November 25, 2020 as DOI: 10.1124/molpharm.120.000094 This article has not been copyedited and formatted. The final version may differ from this version. Distinct regulation of cardiac fibroblast proliferation and transdifferentiation by classical and novel protein kinase C isoforms: possible implications for new antifibrotic therapies S. Tuuli Karhu, Heikki Ruskoaho, Virpi Talman* Affiliations Downloaded from STK, HR, and VT: Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Finland molpharm.aspetjournals.org *Corresponding author at ASPET Journals on September 30, 2021 1 Molecular Pharmacology Fast Forward. Published on November 25, 2020 as DOI: 10.1124/molpharm.120.000094 This article has not been copyedited and formatted. The final version may differ from this version. Running title: PKC agonists inhibit cardiac fibroblast activation Corresponding author: Virpi Talman Division of Pharmacology and Pharmacotherapy Faculty of Pharmacy University of Helsinki P.O. Box 56 (Viikinkaari 5E) FI-00014 Helsinki, FINLAND Downloaded from Tel: +358504480768 Email: [email protected] molpharm.aspetjournals.org Number of text pages: 35 Number of tables: 0 Number of figures: 4 at ASPET Journals on September 30, 2021 Number of references: 55 Number of words in the Abstract: 249 Number of words in the Introduction: 728 Number of words in the Discussion: 1459 Abbreviations: α-SMA, α-smooth muscle actin; aPKC, atypical protein kinase C isoform; BrdU, 5-bromo-2’-deoxyuridine; CF, cardiac fibroblast; cPKC, classical protein kinase C isoform; DDR2, discoidin domain receptor 2; ECM, extracellular matrix; ERK, extracellular signal-regulated kinase; HCA, high-content analysis; LDH, lactate dehydrogenase; MTT, 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; nPKC, novel protein kinase C isoform; PKC, protein kinase C 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Protein Kinase C As a Therapeutic Target in Non-Small Cell Lung Cancer
    International Journal of Molecular Sciences Review Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer Mohammad Mojtaba Sadeghi 1,2, Mohamed F. Salama 2,3,4 and Yusuf A. Hannun 1,2,3,* 1 Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA; [email protected] 2 Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; [email protected] 3 Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA 4 Department of Biochemistry, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Dakahlia Governorate, Egypt * Correspondence: [email protected] Abstract: Driver-directed therapeutics have revolutionized cancer treatment, presenting similar or better efficacy compared to traditional chemotherapy and substantially improving quality of life. Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition. Citation: Sadeghi, M.M.; Salama, PKC isoforms α, ", η, ι, ζ upregulation has been reported in lung cancer, and overexpression correlates M.F.; Hannun, Y.A. Protein Kinase C with worse prognosis in NSCLC patients.
    [Show full text]
  • Effectors and Potential Targets Selectively Upregulated in Human KRAS-Mutant Lung Adenocarcinomas
    bioRxiv preprint doi: https://doi.org/10.1101/041137; this version posted June 4, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas Jinyu Li1, Raffaella Sordella2, and Scott Powers1,2,3 1Department of Pathology, Stony Brook University, Stony Brook, NY, 11794 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724 3Corresponding author, email [email protected] Abstract Genetic and proteomic analysis of human tumor samples can provide an important compliment to information obtained from model systems. Here we examined protein and gene expression from the Cancer Genome and Proteome Atlases (TCGA and TCPA) to characterize proteins and protein-coding genes that are selectively upregulated in KRAS-mutant lung adenocarcinomas. Phosphoprotein activation of several MAPK signaling components was considerably stronger in KRAS-mutants than any other group of tumors, even those with activating mutations in receptor tyrosine kinases (RTKs) and BRAF. Co-occurring mutations in KRAS-mutants were associated with differential activation of PDK1 and PKC-alpha. Genes showing strong activation in RNA-seq data included negative regulators of RTK/RAF/MAPK signaling along with potential oncogenic effectors including activators of Rac and Rho proteins and the receptor protein-tyrosine phosphatase genes PTPRM and PTPRE. These results corroborate RAF/MAPK signaling as an important therapeutic target in KRAS-mutant lung adenocarcinomas and pinpoint new potential targets. Introduction How mutationally activated KRAS and other canonical RAS genes malignantly transform cells and how to block this process for therapeutic benefit has been a subject of intense investigation for over thirty years.
    [Show full text]
  • Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in Vitro and in Vivo
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genetik Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in vitro and in vivo - Towards Response Prediction in Cancer Therapy with Kinase Inhibitors Michaela Bairlein Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ. -Prof. Dr. K. Schneitz Prüfer der Dissertation: 1. Univ.-Prof. Dr. A. Gierl 2. Hon.-Prof. Dr. h.c. A. Ullrich (Eberhard-Karls-Universität Tübingen) 3. Univ.-Prof. A. Schnieke, Ph.D. Die Dissertation wurde am 07.01.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 19.04.2010 angenommen. FOR MY PARENTS 1 Contents 2 Summary ................................................................................................................................................................... 5 3 Zusammenfassung .................................................................................................................................................... 6 4 Introduction .............................................................................................................................................................. 8 4.1 Cancer ..............................................................................................................................................................
    [Show full text]
  • Regulation of Matrix Gla Protein by Parathyroid Hormone in MC3T3-E1 Osteoblast-Like Cells Involves Protein Kinase a and Extracellular Signal-Regulated Kinase Pathways
    Journal of Cellular Biochemistry 102:496–505 (2007) Regulation of Matrix Gla Protein by Parathyroid Hormone in MC3T3-E1 Osteoblast-Like Cells Involves Protein Kinase A and Extracellular Signal-Regulated Kinase Pathways Supaporn Suttamanatwong,1 Renny T. Franceschi,2 Ann E. Carlson,1 and Rajaram Gopalakrishnan1* 1Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, Minnesota 55455 2Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan 48109 Abstract Inhibition of osteoblast-mediated mineralization is one of the major catabolic effects of parathyroid hormone (PTH) on bone. Previously, we showed that PTH induces matrix g-carboxyglutamic acid (Gla) protein (MGP) expression and established that this induction is critical for PTH-mediated inhibition of osteoblast mineralization. In the present study, we focus on the mechanism through which PTH regulates MGP expression in osteoblastic MC3T3-E1 cells. Following transient transfection of these cells with a À748 bp murine MGP promoter-luciferase construct (pMGP-luc), PTH (10 À7 M) induced promoter activity in a time-dependent manner with a maximal four- to six fold induction seen 6 h after PTH treatment. Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level. In addition, forskolin (PKA activator) stimulated MGP promoter activity and mRNA levels confirming that PKA is one of the signaling molecules required for regulation of MGP by PTH. Co- transfection of MC3T3-E1 cells with pMGP-luc and MEK(SP), a plasmid encoding the constitutively active form of MEK, led to a dose-dependent increase in MGP promoter activity.
    [Show full text]